A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses

Cancer vaccines using synthetic long peptides (SLP) targeting tumor antigens have been tested in the clinic but the outcomes have been unimpressive, perhaps because these peptides elicit predominantly CD4(+) T cell responses. We hypothesized that enhanced delivery of peptide antigens to, and uptake...

Descripción completa

Detalles Bibliográficos
Autores principales: Arbelaez, Carlos A., Estrada, Juan, Gessner, Melissa A., Glaus, Charles, Morales, Agnieszka B., Mohn, Deanna, Phee, Hyewon, Lipford, J. Russell, Johnston, James A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661730/
https://www.ncbi.nlm.nih.gov/pubmed/33298945
http://dx.doi.org/10.1038/s41541-020-00253-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661730/
https://www.ncbi.nlm.nih.gov/pubmed/33298945
http://dx.doi.org/10.1038/s41541-020-00253-9

Ejemplares similares